Systems for rapid development of high sensitivity multiplex assays for biothreat

Information

  • Research Project
  • 8522256
  • ApplicationId
    8522256
  • Core Project Number
    R01AI096228
  • Full Project Number
    5R01AI096228-03
  • Serial Number
    096228
  • FOA Number
    RFA-AI-10-017
  • Sub Project Id
  • Project Start Date
    8/22/2011 - 12 years ago
  • Project End Date
    7/31/2015 - 8 years ago
  • Program Officer Name
    REPIK, PATRICIA M.
  • Budget Start Date
    8/1/2013 - 10 years ago
  • Budget End Date
    7/31/2014 - 9 years ago
  • Fiscal Year
    2013
  • Support Year
    03
  • Suffix
  • Award Notice Date
    7/26/2013 - 10 years ago
Organizations

Systems for rapid development of high sensitivity multiplex assays for biothreat

DESCRIPTION (provided by applicant): Diagnostic tests are a critical component of an effective strategy to detect and treat biothreat agents. But pathogen evolution or engineering of biothreat pathogens can result in structures that are no longer recognized by diagnostic assays. Next generation biothreat diagnostics will need to permit rapid and flexible assay development to counteract changes that evade diagnostic detection. In this proposal we describe collaborative investigations to develop materials and protocols for flexible and rapid development of multiplex protein detection assays. As a test of these materials and procedures, we will develop a prototype multiplex diagnostic assay to detect and discriminate strains of Ebola virus (EBOV). This development utilizes innovative recombinant systems to develop suitable EBOV antigen, and engineered antibodies, and relies on screening and selection to both shape antibody affinity and to minimize the likelihood of nonspecific interaction when developing multiplex assays. In this proposal we will also explore the development of stable fluorescent reporters and new optical systems to significantly boost the sensitivity of multiplex detection. The system will be tested by simulating an expansion of the multiplex test and testing the effects of our screening concepts. The final optimized assay will be ready for regulated diagnostic development or will be flexible enough to accept new analyte assays the meet clinical and market demands.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R01
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
    791678
  • Indirect Cost Amount
    93679
  • Total Cost
    885357
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:885357\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZAI1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    LUMINEX CORPORATION
  • Organization Department
  • Organization DUNS
    965476641
  • Organization City
    AUSTIN
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    787276101
  • Organization District
    UNITED STATES